Abstract
Background. Migraine is a common chronic disorder that ranks third in the disability-adjusted life years among nervous system disorders.
It is well known that migraine is strongly associated with the depression/anxiety disorders; there is overwhelming data suggesting common mechanisms underlying migraine and depression, including involvement of the neurotransmitter systems, such as calcitonin gene-related peptide (CGRP).
Aim. Efficacy of fremanezumab in patients with chronic migraine (CM) and concomitant depression.
Methods. A total of 48 patients aged 23–57 years with the established diagnosis of CM and depression took part in the study. Fremanezumab in a dose of 225 mg was administered monthly throughout 6 months. Clinical interviewing and headache diary assessment were performed every month, and the Hamilton Depression Inventory (Hamilton Depression Rating Scale) was filled during the first visit, on months 3 and 6.
Results. A significant decrease in the headache frequency with the steady increase of effect by month 3 of therapy and the effect persistence by month 6 of therapy is reported in patients with CM and depression. A significant decrease in the depression scores based on the Hamilton Depression Rating Scale is observed.
Conclusion. Fremanezumab can be used as one of the first-line drugs for treatment of patients with CM and concomitant depression.
Keywords. Migraine, monoclonal antibodies, chronic migraine, depression, fremanezumab, CGRP.
It is well known that migraine is strongly associated with the depression/anxiety disorders; there is overwhelming data suggesting common mechanisms underlying migraine and depression, including involvement of the neurotransmitter systems, such as calcitonin gene-related peptide (CGRP).
Aim. Efficacy of fremanezumab in patients with chronic migraine (CM) and concomitant depression.
Methods. A total of 48 patients aged 23–57 years with the established diagnosis of CM and depression took part in the study. Fremanezumab in a dose of 225 mg was administered monthly throughout 6 months. Clinical interviewing and headache diary assessment were performed every month, and the Hamilton Depression Inventory (Hamilton Depression Rating Scale) was filled during the first visit, on months 3 and 6.
Results. A significant decrease in the headache frequency with the steady increase of effect by month 3 of therapy and the effect persistence by month 6 of therapy is reported in patients with CM and depression. A significant decrease in the depression scores based on the Hamilton Depression Rating Scale is observed.
Conclusion. Fremanezumab can be used as one of the first-line drugs for treatment of patients with CM and concomitant depression.
Keywords. Migraine, monoclonal antibodies, chronic migraine, depression, fremanezumab, CGRP.
For citation:Timokhovich A.Yu., Berdnikova A.V., Latysheva N.V. Efficacy of fremanezumab in patients with chronic migraine and concomitant depression. Clinical review for general practice. 2024; 5 (10): 113–117 (In Russ.). DOI: 10.47407/kr2024.5.10.00504
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
